Exelixis Inc

Change company Symbol lookup

Select an option...

EXEL Exelixis Inc

ATRC AtriCure Inc

CTRA Coterra Energy Inc

CINF Cincinnati Financial Corp

ATOM Atomera Inc

IEAWW Infrastructure and Energy Alternatives 27 March 2023 *W EXP 03/27/2023

SLAC Social Leverage Acquisition Corp I

CNNXF Cannamerica Brands Corp

BA Boeing Co

COP Conocophillips

Go

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.